Results 131 to 140 of about 210,353 (388)

Clinical Experience with Warfarin Sodium [PDF]

, 1958
M. Toohey
openalex   +1 more source

Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2017
Background The original non–vitamin K antagonist oral anticoagulant (NOAC) trials in nonvalvular atrial fibrillation (AF) enrolled patients with native valve pathologies.
K. Pan, D. Singer, B. Ovbiagele, Yi-Ling Wu, Mohamed A. Ahmed, Meng Lee   +5 more
semanticscholar   +1 more source

Pharmacology of heparin and warfarin

Journal of the American College of Cardiology, 1986
Thromboembolic obstruction to three major components of the circulation--arterial, venous and intravascular foreign surfaces--contributes to premature death and disability in Western society. In many, but not all, of these conditions associated with thromboembolism, heparin and warfarin are the drugs of choice. It is the purpose of this presentation to
Sanford N. Gitel, Stanford Wessler
openaire   +3 more sources

Refractory anaemia in a patient with end‐stage heart failure secondary to aortic stenosis

ESC Heart Failure, EarlyView.
Jiayu Liang, Suxin Luo, Bi Huang
wiley   +1 more source

A Multicenter, Open‐Label Study to Assess the Safety of Nebulized Tissue Plasminogen Activator for the Acute Treatment of Pediatric Plastic Bronchitis: The PLATyPuS Trial

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
ABSTRACT Introduction Pediatric plastic bronchitis (PB) is a rare complication of surgically palliated congenital heart disease (CHD). Fibrin casts obstruct airways and can cause respiratory distress. There are no therapeutics approved by the United States Food and Drug Administration to treat PB, but inhaled tissue plasminogen activator (tPA) has been
Kathleen A. Stringer, David Goldberg, Sharon Chen, Philip Thrush, Eric M. Graham, Adam Lubert, Jeffrey Myers, Laura McLellan, Thomas Flott, Samya Nasr, Kurt R. Schumacher   +10 more
wiley   +1 more source

Comparison of Temporary Interruption of Warfarin Therapy for 3 and 5 days before Surgery in Thailand: A Randomized Controlled Trial

Siriraj Medical Journal, 2017
Objective: The ACCP guideline 2008 recommended cessation of warfarin five days before surgery. However, based on the observation of the clinical practice at Siriraj Hospital, we suggested a shorter period of three days before surgery.
Angsu Chartrungsan, Pansak Laksanabunsong, Akarin Nimmannit, Bundarika Bundarika Suwanawiboon, Naravat Poungvarin, Wanchai Wongkornrat, Kriangkrai Tantiwongkosri, Worawong Slisatkorn, Pranya Sakiyalak, Punnarerk Thongcharoen, Thaworn Subtaweesin, Somchai Sriyoschati, Teeravit Phanchaipetch   +12 more
doaj  

Number needed to treat for net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation

Journal of Arrhythmia
Background Oral anticoagulants (OAC) can reduce ischemic stroke/systemic embolism (SSE) in patients with non‐valvular atrial fibrillation (AF) while increasing the risk of major bleeding. We aimed to analyze the number needed to treat for the net benefit
Rungroj Krittayaphong, Satchana Pumprueg, Ahthit Yindeengam, Gregory Y. H. Lip   +3 more
doaj   +1 more source

Association of Omeprazole‐Related Myopathy With Drug–Drug and Drug–Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case–Control Study

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
ABSTRACT Background Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy.
Eugene Jeong, Aditi Shendre, Yu Su, Xingyi Guo, Lang Li, You Chen   +5 more
wiley   +1 more source

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism

Journal of Thrombosis and Thrombolysis, 2016
Venous thromboembolism (VTE) is a serious and often fatal medical condition with an increasing incidence. The treatment of VTE is undergoing tremendous changes with the introduction of the new direct oral anticoagulants and clinicians need to understand ...
D. Witt, N. Clark, S. Kaatz, T. Schnurr, J. Ansell   +4 more
semanticscholar   +1 more source

Development and Verification of Virtual Population Models for Predicting Drug Pharmacokinetics in Ethnic North American Populations

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Ethnic variabilities can affect the outcome of drug pharmacokinetics (PK) and drug–drug interactions (DDI). This work aimed to develop four North American (NA) sub‐populations: White, African American, Asian American, and Hispanic_Latino suitable for physiologically based pharmacokinetic (PBPK) modeling and simulations.
Udoamaka Ezuruike, Jean Dinh, Eman El‐Khateeb, Alex Blenkinsop, Oliver Hatley, Iain Gardner   +5 more
wiley   +1 more source